Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 361

Sort by

Sort Order Select

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

Blood (2019) 134 (Supplement_1): 635.

https://doi.org/10.1182/blood-2019-126128

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

An OCT2 / OCA-B / MEF2B Ternary Complex Controls the Activity and Architecture of an Essential Locus Control Region for Normal and Malignant Germinal Center B-Cells

Johannes C Hellmuth, MD, Chi-Shuen Chu, PhD, Rajat Singh, PhD, Lucy A Skrabanek, PhD, Ashley Doane, Olivier Elemento, PhD, Robert G. Roeder, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 24.

https://doi.org/10.1182/blood-2019-130692

Published: 2019

Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD

Blood (2019) 134 (Supplement_1): 3550.

https://doi.org/10.1182/blood-2019-129930

Published: 2019

Journal Articles

A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center

Marissa A. Just, MD, Joanna Robles, MD, Karan R. Kumar, MD MS, Andrew Yazman, BS, MMCi, Jennifer A. Rothman, MD, Kristy S. Pahl, MD

Blood (2019) 134 (Supplement_1): 3471.

https://doi.org/10.1182/blood-2019-129398

Published: 2019

Journal Articles

Quality of Life and Patient Reported Outcomes in Severe Chronic Neutropenia

Thomas F. Michniacki, MD, Lauren E. Merz, MDMSc, Harlan McCaffrey, MA MS, James A. Connelly, MD, Kelly J. Walkovich, MD

Blood (2019) 134 (Supplement_1): 3449.

https://doi.org/10.1182/blood-2019-126808

Published: 2019

Journal Articles

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Elyse C Page, BSc, Susan L Heatley, PhD MD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Paul Q Thomas, PhD, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 1462.

https://doi.org/10.1182/blood-2019-126244

Published: 2019

Journal Articles

High Mobility Group A1 Chromatin Regulators: Key Epigenetic Switches and Therapeutic Targets Required for Leukemic Transformation in JAK2 Mutant MPN

Liping Li, MD PhD, Wenyan Lu, PhD, Alison R. Moliterno, MD, Lingling Xian, MD PhD, Joseph Kim, BS, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 1680.

https://doi.org/10.1182/blood-2019-130262

Published: 2019

Journal Articles

Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients

Michelle E. Savedra, MT(ASCP), Jessica L. Szuberski, MLS ASCP, Tavanna R. Porter, MS, LCGC, Molly S. Hein, Phuong L. Nguyen, MD, Min Shi, MD PhD, Aruna Rangan, MD, James D. Hoyer, MD, Jennifer L. Oliveira, MD

Blood (2019) 134 (Supplement_1): 1011.

https://doi.org/10.1182/blood-2019-131125

Published: 2019

Journal Articles

Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease

Karl Ewins, Fionnuala Ni Ainle, PhD, Eoghan Dunlea, MB BCh MRCPI, Sarah Kelliher, MBBS, Vicky Sandys, MB BCh MRCPI, Hannorah Rooney, BM BCh MRCPI, Lily Macken, MB BCh MRCPI, Ni Cheallaigh Cliona, MB BCH MRCPI PhD

Blood (2019) 134 (Supplement_1): 4702.

https://doi.org/10.1182/blood-2019-130371

Published: 2019

Journal Articles

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Eek, PhD, Cristina Ivanescu, PhD, Leanne Kool-Houweling, MSc, David Cella, PhD

Blood (2019) 134 (Supplement_1): 4763.

https://doi.org/10.1182/blood-2019-123056

Published: 2019

Journal Articles

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Robin Sanderson, MRCP,FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 249.

https://doi.org/10.1182/blood-2019-125647

Published: 2019

Journal Articles

High Mobility Group A1 Chromatin Regulators Function As Critical Drivers of Leukemogenesis in Preclinical Models of Relapsed, Pediatric B-Cell ALL

Liping Li, MD PhD, Katharina Hayer, Lingling Xian, MD PhD, Li Luo, PhD, Leslie Cope, Andrei Thomas-Tikhonenko, PhD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 3946.

https://doi.org/10.1182/blood-2019-130261

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Johannes Oldenburg, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, MD, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria, Mark Reding

Blood (2019) 134 (Supplement_1): 4943.

https://doi.org/10.1182/blood-2019-128140

Published: 2019

Journal Articles

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Stephane Lepretre, MD, Chantal Touboul, Alain Flinois, PhD, Lucie Kutikova, PhD, Kahina Makhloufi, MD, Jean-Vannak Chauny, PharmD, Gaëlle Désaméricq

Blood (2019) 134 (Supplement_1): 5123.

https://doi.org/10.1182/blood-2019-122466

Published: 2019

Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA

Blood (2019) 134 (Supplement_1): 5898.

https://doi.org/10.1182/blood-2019-128517

Published: 2019

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Can Li, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 5538.

https://doi.org/10.1182/blood-2019-121933

Published: 2019

NARROW

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

An OCT2 / OCA-B / MEF2B Ternary Complex Controls the Activity and Architecture of an Essential Locus Control Region for Normal and Malignant Germinal Center B-Cells

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center

Quality of Life and Patient Reported Outcomes in Severe Chronic Neutropenia

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

High Mobility Group A1 Chromatin Regulators: Key Epigenetic Switches and Therapeutic Targets Required for Leukemic Transformation in JAK2 Mutant MPN

Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients

Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

High Mobility Group A1 Chromatin Regulators Function As Critical Drivers of Leukemogenesis in Preclinical Models of Relapsed, Pediatric B-Cell ALL

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only